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This document updates and expands the recommendations on primary prophylaxis of invasive fungal diseases
(IFD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients, published in 2009 by the
Gruppo Italiano Trapianto Midollo Osseo (GITMO). A consensus process was undertaken to describe and
evaluate current information and practice regarding risk stratiﬁcation and primary antifungal prophylaxis
during the pre-engraftment and postengraftment phases after allo-HSCT. The revised recommendations were
based on the evaluation of recent literature including a large, prospective, multicenter epidemiological study of
allo-HSCT recipients conducted among the GITMO transplantation centers during the period of 2008 to 2010. It
is intended as a guide for the identiﬁcation of types and phases of transplantation at low, standard, and high
risk for IFD, according to the underlying disease, transplantation, and post-transplantation factors. The risk
stratiﬁcation was the critical determinant of the primary antifungal approach for allo-HSCT recipients.
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14.02.018INTRODUCTION
In 2009, an expert panel (EP), representative of theGruppo
Italiano Trapianto Midollo Osseo (GITMO), published the re-
sults of a consensus process on the prophylaxis and therapyof
invasive fungal diseases (IFD) in allogeneic hematopoietic
stem cell transplantation (allo-HSCT) to improve awareness,Transplantation.
C. Girmenia et al. / Biol Blood Marrow Transplant 20 (2014) 1080e1088 1081diagnosis, and management of IFD, and to better deﬁne the
current prophylactic and therapeutic options in the clinical
practice [1]. Important issues considered in the consensus
processwere the deﬁnition of the risk level for IFD in different
transplantation settings and different transplantation phases
as critical determinants in the antifungal prophylaxis
approach to allo-HSCT recipients. As the vulnerability of allo-
HSCT recipients to IFD is multifactorial, no single risk strati-
ﬁcation system can be identiﬁed. However, the EP agreed that
an operational distinction could be made between standard
and high-risk conditions for IFD, mainly invasive aspergil-
losis, during and after the engraftment phase. The conse-
quence of this dichotomous classiﬁcation was the indication
or the lack of indication for the use of a mold-active primary
antifungal prophylaxis (PAP) during and after the engraft-
ment period. In addition, in these GITMO recommendations,
the deﬁnition of patients at high risk for IFD, for whom a
mold-active PAP would be recommended, was based on
limited literature evidence, mainly derived from local expe-
rience, and was difﬁcult to apply in clinical practice.
Over a period of 3 years (2008 to 2010), GITMO conducted
a large, prospective epidemiological study involving 30 Ital-
ian transplantation centers to assess the current incidence,
risk, and prognostic factors of IFDs in allo-HSCT recipients
[2]. In a real-life scenario representative of the current allo-
HSCT practice, this study was able to identify speciﬁc
transplantation settings with a different risk of IFD during
the pre-engraftment and postengraftment phases. Based on
these original epidemiological GITMO data and on recent
literature evidence, a new Consensus Development Confer-
ence Project was convened by GITMO with the aim to revise
and update recommendations on PAP in patients undergoing
allo-HSCT.Table 1
Strength of Recommendation and Quality of Evidence
Category/
Grade
Deﬁnition
Strength of Recommendation
A Good evidence to support a recommendation for or
against use.
B Moderate evidence to support a recommendation for or
against use.
C Poor evidence to support a recommendation.
Quality of Evidence
I Evidence from  1 properly randomized, controlled
trial.
II Evidence from  1 well-designed clinical trial, without
randomization; from cohort or case controlled
analytic studies (preferably from > 1 center); from
multiple time-series; or from dramatic results from
uncontrolled experiments.
III Evidence from opinions of respected authorities, based
on clinical experience, descriptive studies, or reports
of expert committees.
Data from Freifeld AG, Bow EJ, Sepkowitz KA, et al [5].DESIGN AND METHODS
The EP included 19 individuals selected in view of their expertise in
research and clinical practice of allo-HSCT. An advisory committee chaired
by 4 clinicians (G.B., C.G., F.C., and A.R.) and a statistician (A.P.) with expertise
in clinical epidemiology assured the proper methodology of the process. Of
the 19 panelists, 11 had been involved in the previous GITMO epidemio-
logical study.
The goal of the project was to develop recommendations for PAP of IFD
in allo-HSCT. The areas of major concern in the PAP of IFD in allo-HSCT were
selected by generating clinical key questions using the criterion of clinical
relevance, ie, the impact on the management of patients and risk of inap-
propriateness, through a Delphi process [3].
Before the ﬁrst meeting, the advisory committee examined the current
state of knowledge regarding PAP of IFD in allo-HSCT, identiﬁed key ques-
tions, and drafted statements to address those questions. A systematic re-
view of the literature on the epidemiology and PAP of IFDs in allo-HSCT
populations (using the terms “epidemiology”, “fungal infections,” “alloge-
neic stem cell transplant,” and “antifungal prophylaxis” for the search) was
performed on PubMed database, limiting the choice to English-language
articles. Only articles including large single-center or multicenter series of
allo-HSCT patients were considered. Based on the reviewed literature and
on the results of the GITMO survey, the advisory committee formulated
some recommendations. In detail, the conditions that proved to be signiﬁ-
cant risk factors for IFD in the different phases after transplantation repre-
sented the criteria for an evidence-based deﬁnition of PAP strategy; other
expertise-based recommendations were proposed when relevant areas
could not be addressed on the basis of the available evidence but when
indirect evidence could support a statement. The literature review and the
drafted statements were circulated by electronic mail to the EP members.
With a 3-month interval, 2 meetings were held by the EP group in 2013:
each panelist scored his/her agreement with the statements made by the
advisory committee and the other panelists and provided suggestions for
rephrasing. The ensuing comments were centrally combined for a subse-
quent round of electronic consultation, and agreement on the statements
and the full body of recommendations were deﬁnitively approved.
The overall goal of the meetings was to reach a deﬁnite consensus over
question-speciﬁc statements for which there was disagreement during theﬁrst-round postal phase. The nominal group technique [4] was used,
through which participants were ﬁrst asked to comment in round-robin
fashion on their preliminary votes and then to propose a new vote. If an
80% consensus on the statement was not achieved, the choices were dis-
cussed and a second vote taken. If an 80% consensus was still not attained,
the issue was declared unresolved and no further attempt was made. The EP
used a systematic weighting of the level and grade of the evidence for
making a recommendation (Table 1) [5].
RESULTS
The key questions that were considered relevant for the
present recommendations are the risk stratiﬁcation and the
choice of drugs for PAP.
Deﬁnition of Risk for Invasive Fungal Disease
The level of risk for IFD in allo-HSCT recipients depends
on several factors, including host characteristics, underlying
hematological disease conditions, type of transplantation,
and post-transplantation complications. Risk may vary in
different patients and also in the same patient at different
times along the transplantation course [2,6-15]. Historically,
neutropenia and acute and chronic graft-versus-host-disease
(a-GVHD and c-GVHD) represent the major risk factors for
infections during both the engraftment and post-
engraftment phases. In epidemiological studies on pop-
ulations who underwent transplantation in the previous
decades, the vast majority of IFDs were documented late
after engraftment and were generally associated with
occurrence of GVHD [8,14,15]. In the more recent GITMO
survey, more than one half of cases of IFD, mainly invasive
aspergillosis, occurred during the early period and were
generally associated with pre-engraftment length and
deepness of neutropenia [2]. The high rate of IFD docu-
mented in this early phase after transplantation was related
to the high number of patients who had 1 or more conditions
associated with a signiﬁcantly increased risk of early IFD.
These risk factors included an IFD during the 6 months
before transplantation, active acute leukemia at the time of
transplantation, unrelated cord blood (CB), or unrelated
volunteer donor (UD) graft: the incidence of early IFDs for
patients with these risk factors was respectively 16%, 12%,
12%, and 6.4%. The high risk of reactivation early after allo-
HSCT is well known in patients with a history of invasive
aspergillosis before transplantation, and, in these patients,
secondary prophylaxis is strongly recommended [16]. The
high risk for the development of early IFDs in CB transplant
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to several reasons, including delayed engraftment and
naiveté of donor T cells (Table 2) [17-23]. The observation of a
high rate of early IFDs in patients with active acute leukemia
at the time of transplantation represents an original ﬁnding
of the GITMO survey. Severe immunologic impairment
associated with active disease, multiple intensive chemo-
therapy treatments, and late engraftment, frequently seen in
these patients, justiﬁes the high early post-transplantation
risk of IFD [24-26].
GVHD (see standard criteria for diagnosis and staging
[27]) represents a well-known risk factor for IFD in allo-
HSCT. However, GVHD is a heterogeneous syndrome,
which may signiﬁcantly differ according to stem cell source,
type of donor, and type of GVHD prophylaxis, with a
consequent variable risk of IFD. The increased incidence of
IFD in patients with grade III and IV a-GVHD, as compared
with those with grade II, observed in the GITMO study
conﬁrms previous evidence of a correlation between GVHD
severity, intensity of immunosuppressive therapy, and risk
of IFD [8]. Donor type and the dynamic evolution of GVHD
seem to be determinant factors affecting the infectious risk.
The GITMO study showed that the risk for IFD in patients
with grade II to IV a-GVHD not followed by extensive c-
GVHD was low in patients who underwent transplantation
from a matched related donor (MRD) (2.3%) and high in
those who underwent transplantation from an alternative
donor (mismatched related donor [MMRD], UD, and CB)
(10%). When a-GVHD was followed by c-GVHD, the risk was
high in either transplantations from MRD (10%) or, partic-
ularly, from alternative donors (25%). Of interest, the rate of
IFDs in patients with c-GVHD not preceded by a-GVHD (also
called de novo GVHD) was relatively low (< 4%) in all types
of transplantation.
These data suggest the possibility of stratifying the in-
fectious risk in patients with GVHD, taking into account the
transplantation setting and clinical presentation of GVHD.Table 2
Characteristics and Risk for Invasive Fungal Disease in Cord Blood and Haploident
Author, Year Type of Transplantation, Population (n)
Cord blood allo-HSCT
Saavedra, 2002 [17] Single, adults (27)
Parody, 2006 [18] Single (48)
Miyacoshi, 2007 [20] Reduced-intensity conditioning, adults (128)
Cahu, 2009 [21] Single (4) or double (27), adults
Sauter, 2011 [22] Double, without ATG (72)
Ruggeri, 2011 [23] Double, children and adults (35)
GITMO study [2] Not reported, children and adults (179)
Haploidentical allo-HSCT
Huang, 2006 [28] Unmanipulated, children and adults (171)
Rizzieri, 2007 [29] Unmanipulated, G-CSF primed PB
transplantation, adults (49)
Huang, 2009 [30] Unmanipulated, children (50)
Dodero, 2009 [31] Ex vivo and in vivo T cell depleted, RIC,
CD8-depleted DLI (28)
Federmann, 2012 [32] CD3/CD19 depleted, adults (61)
Sun, 2012 [33] Unmanipulated, adults and children (291)
Raiola, 2013 [34] Unmanipulated, BM transplantation, adults (50)
Di Bartolomeo, 2013 [35] Unmanipulated, G-CSF primed BM
transplantation, adults (80)
GITMO study [2] Not reported, adults (72)
Allo-HSCT indicates allogeneic hematopoietic stem cell transplantation; IFD, inva
G-CSF, granulocyte-colony stimulating factor; PB, peripheral blood; BM, bonemarro
not reported; vori; voriconazole; posa, posaconazole.Another population considered at high risk of infection is
represented by patients undergoing transplantation from
haploidentical donor, particularly when the graft is T cell
depleted and is not followed by adoptive transfer of antigen-
speciﬁc cells [28-35]. However, data from the literature are
controversial and the rate of IFD seems to be variable in
relation with the type of T cell depletion and of immuno-
suppressive regimen (Table 2).
With regard to the intensity of the conditioning regimen,
a reduced risk of early IFD may be hypothesized in patients
receiving a nonmyeloablative or reduced-intensity trans-
plantation. However, both literature evidence and the GITMO
survey, in particular, do not demonstrate any signiﬁcant
difference in the risk of IFD during the various phases after
transplantation to suggest a tailored PAP strategy based on
the intensity of the conditioning regimen [2].
Iron overload has been associated with increased risk of
IFD in hematologic patients, and in allo-HSCT recipients, it
has been shown to be correlated with pulmonary mold
infection, mainly during the ﬁrst 30 days from trans-
plantation [10,36-38].
The EP agreed that 3 time periods should be distinguished
in allo-HSCT: an early phase (from day 1 to 40), a late phase
(from day 41 to 100), and a very late phase (after day 100)
[8,12]. The 3 phases reﬂect the risk of IFD being associated
with neutropenia (early), with a-GVHD and the early im-
mune recovery (late), and with late a-GVHD or c-GVHD,
together with late immunologic recovery (very late).
The EP agreed that patients could be stratiﬁed according to
theneed of a PAP strategy in 3 groups: those not requiring PAP
(low-risk), those requiring a Candida-active PAP (standard
risk), and those requiring a mold-active PAP (high risk). Dur-
ing the early and late post-transplantation phase, the GITMO
data suggest that patients should be classiﬁed either at stan-
dardorhigh risk of IFD,with nopatient qualifying for low risk.
During the very late post-transplantationphase, patientsmay
be classiﬁed at low, standard, and high risk of IFD.ical allo-HSCT Studies
Primary Antifungal Prophylaxis Incidence of IFDs
Overall/Early Phase, (%)
Fluconazole plus aerosolized AmB 11/7.4
Fluconazole 23/10
Fluconazole or micafungin 10.9/10.2
Fluconazole 10/10
Mica during conditioning followed
by vori or posa
18/14
Fluconazole 34/12
Not reported 17.3/11.9
Fluconazole 5.2/NR Most of IFD late
or very late
Not reported 8.2/NR
Fluconazole 2/NR Only 1 IFD
Itraconazole 10.7/NR Only 1 case of
aspergillosis
Not reported NR. Only 2 very late deaths
due to IFD
Fluconazole 13.4/7.9
Fluconazole 16/NR
Fluconazole 14/7
Not reported 8.2/5.4
sive fungal diseases; AmB, amphotericin B; ATG, antithymocyte globulin;
w; RIC, reduced-intensity conditioning; DLI, donor lymphocyte infusion; NR,
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particulate air ﬁltration with positive pressure, proved to be
of crucial importance in the prevention of airway ﬁlamen-
tous fungi infections. Therefore, their use may condition the
PAP strategy during the in-hospital stay of the patients. Ac-
cording to the recent epidemiological ﬁndings (most centers
that participated in the GITMO survey were equipped with
air ﬁltration systems), the use of these measures was asso-
ciated with a low rate of hospital-acquiredmold infections in
standard-risk patients who, therefore, require only a
Candida-active PAP. By contrast, air ﬁltration systems may be
insufﬁcient in high-risk patients.Recommendations
1. In the early phase after allo-HSCT, for patients to be
deﬁned at high risk of IFD, thus requiring amold-active
PAP, they should have at least 1 of the following risk
factors:
a. acute leukemia with active disease at the time of
transplantation (AII),
b. CB transplantation (AII),
c. grade III or IV a-GVHD after any type of trans-
plantation (AII),
d. MMRD or UD with 1 or more of the following
additional risk factors: grade II a-GVHD, a steroid
dose  2 mg/kg/day for at least 1 week, cytomeg-
alovirus (CMV) disease, recurrent CMV infection,
prolonged neutropenia (polymorphonuclear
neutrophil <500/mL for more than 3 weeks), or iron
overload (BIII),
e. steroid refractory/dependent a-GVHD after any type
of transplantation, deﬁned as no response after 7
days of corticosteroid treatment or clear progres-
sion after 5 days and recurrence of a-GVHD signs
with tapering of the corticosteroid dose and need of
a chronic steroid therapy [39] (AIII).
2. In the early phase after allo-HSCT, all remaining pa-
tients not included in the high-risk category (standard
risk) require a Candida-active PAP (AI).
3. In the late phase after allo-HSCT, patients at high risk of
IFD requiring a mold-active PAP should have at least 1
of the following risk factors:
a. acute grade III or IV GVHD after any type of trans-
plantation (AII),
b. transplantation fromMMRD or UD and 1 or more of
the following additional risk factors: grade II
a-GVHD, a steroid dose  2 mg/kg/day for at least 1
week, CMV disease, recurrent CMV infection, or
recurrent neutropenia (polymorphonuclear
neutrophil <500/mL for more than 1 week) (BIII),
c. steroid refractory/dependent a-GVHD after any type
of transplantation (see above deﬁnition) (AIII).
4. All remaining patients not included in the high-risk
category (standard risk) require a Candida-active PAP
(BI).
5. In the very late phase after allo-HSCT, patients at high
risk of IFD requiring a mold-active PAP are those with:
a. persistent or late-onset grade III or IV a-GVHD (AII),
b. persistent or late-onset steroid refractory/depen-
dent a-GVHD after any type of transplantation (AII),
c. persistent or late-onset grade II a-GVHD in patients
after transplantation from MMRD or UD (BIII),
d. extensive c-GVHD when preceded by a-GVHD (AII).7. In the very late phase after allo-HSCT, patients at
standard risk for IFD requiring a Candida-active PAP
are those with limited c-GVHD who receive steroid-
free immunosuppression (in general, a calcineurin in-
hibitor) and those with de novo c-GVHD (BII).
8. In the very late phase after allo-HSCT, patients at low
risk for IFD not requiring any PAP are those free of any
type of GVHD and free of steroid therapy (AII).
PRIMARY ANTIFUNGAL PROPHYLAXIS
The 2009 GITMO Consensus Conference, in agreement
with the international guidelines, recommended, with high
level of evidence (AI), the use of ﬂuconazole and pos-
aconazole as PAP in allo-HSCT patients, at least during the
ﬁrst 75 days after transplantation and in patients with GVHD,
respectively [1]. These recommendations were based on the
results of large prospective multicenter trials that demon-
strated a decrease in the rate of Candida infection and the
overall survival beneﬁt at long-term follow-up associated
with the use of ﬂuconazole as compared with placebo and
the signiﬁcant reduction of the incidence of IFDs, invasive
aspergillosis, in particular, in patients with GVHD who
received posaconazole as compared with those who received
ﬂuconazole [40,41].
Since the GITMO Consensus Conference published in
2009, only few studies on PAP in the allo-HSCT population
have been published [42-51], and only 2 of them were pro-
spective, randomized, multicenter trials [43,46] (Table 3).
In the double-blind trial comparing voriconazole (305
patients) with ﬂuconazole (295 patients), no difference of 6-
month fungal-free survival was observed, and in the vor-
iconazole arm there were no statistically signiﬁcant
reductions in IFD and invasive aspergillosis. A post hoc
subanalysis showed an increased risk of IFD and a poorer
fungal-free survival in patients with acute myeloid leukemia.
Voriconazole signiﬁcantly reduced IFDs (8.5% versus 21%, P¼
.04) and improved fungal-free-survival (78% versus 61%, P ¼
.04) in this population [43]. An open-label study compared
the efﬁcacy and safety of voriconazole (234 patients) versus
itraconazole (255 patients) [46]. The success of prophylaxis
was signiﬁcantly higher with voriconazole than with itra-
conazole (48.7% versus 33.2%, P < .01) as a result of a better
voriconazole tolerability, although there was no difference in
the either the incidence of IFD or survival.
Second-generation triazoles, voriconazole and pos-
aconazole, have some pharmacokinetic limitations related to
possible drug-drug interactions, erratic absorption, and un-
usual toxicities associated with long-term use. These limi-
tations should be considered, particularly in allo-HSCT
patients, who frequently suffer of gastrointestinal diseases
and receive several other treatments, such as immunosup-
pressants, anticonvulsants, and other antimicrobial agents,
which may interact with other drugs, with possible recip-
rocal modiﬁcation in the pharmacokinetic and additive
toxicity [52]. Drug-drug interaction and metabolic variability
with the risk of either subtherapeutic levels or toxicity
related to high blood levels has been frequently reported for
voriconazole, whereas the reduced absorption of pos-
aconazole in patients with mucositis or GVHD of the
gastrointestinal tract may determine subtherapeutic con-
centrations with consequent suboptimal efﬁcacy [53]. The
evidence in the pharmacokinetic proﬁles of both vor-
iconazole and posaconazole support the utility of monitoring
blood concentrations (therapeutic drug monitoring [TDM])
of the drugs to ensure optimal systemic exposure [53,54].
Table 3
Main Results of the Studies of Primary Antifungal Prophylaxis in allo-HSCT Patients Published Since 2009
Author, Year Type of Study, Drugs, No. of Patients Results
Martin, 2010 [42] Retrospective, single center. Voriconazole, from day -2
until immunosuppression, (n ¼ 72).
In the ﬁrst 120 days after transplantation, only 2 patients
developed IFD. Only 14% of the patients required
interruption of prophylaxis because of toxicity.
Wingard, 2010 [43] Prospective, randomized, double-blind, multicenter.
Voriconazole (n ¼ 305) versus ﬂuconazole (n ¼ 295) for
100 days, or for 180 days in higher-risk patients.
Despite trends to fewer IFDs (7.3% versus 11.2%, P ¼ .12),
Aspergillus infections (9 versus 17, P ¼ .09), and less
frequent empiric antifungal therapy (24.1% versus 30.2%,
P ¼ .11) with voriconazole, fungal-free survival rates
(75% versus 78%, P ¼ .49) at 180 days were similar with
ﬂuconazole and voriconazole, respectively. Relapse-free
and overall survival and the incidence of severe adverse
events were also similar.
Morello, 2011 [44] Retrospective, single center. AmB deoxycholate inhalation
for a median duration of 16 days in addition to systemic
prophylaxis
(n ¼ 102).
In 16 patients in whom aero-d-AmB was delivered for
< 8 days, because of worsened clinical conditions or poor
compliance, proven or probable airway mold infections
were diagnosed in 3 cases, whereas in 84 patients
receiving aero-d-AmB for > 8 days, 1 possible and 1
probable aspergillosis were diagnosed. At multivariate
analysis, prolonged aero-d-AmB administration retained
an independent protective effect on airways IFDs
(P ¼ .026)
Winston, 2011 [45] Retrospective, single center.
Posaconazole, day 1 to 100, or more, from transplantation
(n ¼ 106)
Breakthrough IFD on posaconazole occurred in 8 patients
(7.5%) within 6 months after SCT; 3 additional patients
developed IFD after discontinuation of prophylactic
posaconazole. Mortality from IFD occurred in 4 patients
(3.7%). Except for nausea in 9 patients, no clinical adverse
event or laboratory abnormality could be attributed to
posaconazole. Mean peak and trough plasma
posaconazole concentrations were relatively low
(400 ng/mL) in neutropenic patients with oral mucositis
and other factors possibly affecting optimal absorption of
posaconazole.
Marks 2011 [46] Prospective, randomized, open label, multicenter.
Voriconazole (n ¼ 234) versus itraconazole (n ¼ 255) for
100 days, or for 180 days in higher-risk patients.
Success of prophylaxis was signiﬁcantly higher with
voriconazole than itraconazole (48.7% versus 33.2%,
P < .01). More voriconazole patients tolerated
prophylaxis for 100 days (53.6% versus 39.0%, P < .01).
There was no difference in incidence of proven/probable
IFD (1.3% versus 2.1%) or survival to day 180 (81.9% versus
80.9%) for voriconazole and itraconazole, respectively.
Nihtinen, 2012 [47] Retrospective, single center in patients with acute GVHD.
AmB deoxycholate inhalation for a median duration of
84 days (n¼ 354) versus historical control (n ¼ 257). No
systemic prophylaxis.
Invasive aspergillosis was documented in 2.5% of patients
versus 6.6% of controls. The median time to the diagnosis
of invasive aspergillosis was155 days and 95 days from
transplantation, respectively (P ¼ .2). No discontinuation
of prophylaxis because of side effects was recorded.
Molina, 2012 [48] Prospective pilot study, single center, in children.
Voriconazole (n ¼ 56)
66.1% of patients successfully completed treatment (85.7%
during neutropenic period) without empirical or
preemptive antifungal therapy, adverse effects, or IFD.
One (1.8%) probable IFD. A total of 10 (17.8%) children
developed adverse effects related to voriconazole
prophylaxis, leading to deﬁnitive withdrawal.
Doring, 2012 [49] Retrospective, single center in children.
L-amB (n ¼ 60) versus caspofungin (n ¼ 60) from
day 0 until hospitalization.
No proven breakthrough fungal infection occurred in either
group during the median treatment period of 23 days in
the L-AmB group and 24 days in the caspofungin group.
One patient receiving caspofungin developed probable
invasive aspergillosis. Patients treated with L-AmB had
more drug-related side effects and an increased need for
oral supplementation with potassium, sodium
bicarbonate, and calcium upon discharge as compared
with the caspofungin group. Caspofungin was well
tolerated and safe.
Doring, 2012 [50] Retrospective, single center in patients under 12 years of
age. L-amB or caspofungin during hospitalization,
posaconazole at discharge until day 100, or more, from
transplantation (n¼ 60).
No proven or probable IFD was documented during
treatment with posaconazole as antifungal prophylaxis.
No severe side effects.
El-Cheikh, 2013 [51] Retrospective, single center, haploidentical transplantation.
Micafungin, from conditioning until hospital discharge
(n ¼26).
No IFD at 6 months from transplantation. No patient
discontinued the treatment for drug-related adverse
events.
Allo-HSCT indicates allogeneic hematopoietic stem cell transplantation; IFD, invasive fungal disease; aero-d-AmB, amphotericin B deoxycholate inhalation;
GVHD, graft-versus-host disease; L-amB, liposomal amphotericin B.
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1. Fluconazole (400 mg/day in adults and 8 to 12 mg/kg/
day in children, administered intravenously or orally)is the drug of choice for a Candida-active PAP in any
phase after transplantation in patients at standard risk
for IFDs (AI). It should be continued at least until day
75 from transplantation or until immunosuppressive
Table 4
Recommendations for Primary Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation Patients
Level of Risk for IFD Criteria for the Deﬁnition of the Level of Risk PAP Recommended
Early Phase after Transplantation (Day 0-40) Late Phase after Transplantation (Day 41-100) Very Late Phase after Transplantation (Day >
100)
High risk  Active acute leukemia at the time of trans-
plantation (AII),
 CB transplantation (AII),
 Grade III-IV a-GVHD after any type of
transplantation (AII),
 Transplantation from MMRD or UD and 1 or
more of the following additional risk factors:
grade II a-GVHD, steroid dose  2 mg/kg/day
for at least 1 week, CMV disease, recurrent
CMV infection, prolonged neutropenia (PMN
< 500/mL for more than 3 weeks), iron over-
load (BIII),
 Steroid refractory/dependent a-GVHD after
any type of transplantation (AIII).
 Acute grade III-IV GVHD after any type of
transplantation (AII),
 Transplantation from MMRD or UD and 1 or
more of the following additional risk factors:
grade II a-GVHD, steroid dose  2 mg/kg/day
for at least 1 week, CMV disease, recurrent
CMV infection, recurrent neutropenia (PMN
< 500/mL for more that 1 week) (BIII),
 Steroid refractory/dependent a-GVHD after
any type of transplantation (AIII).
 Persistent or late-onset grade III-IV a-GVHD
(AII),
 Persistent or late-onset steroid refractory/
dependent a-GVHD after any type of
transplantation (AII),
 Persistent or late-onset grade II a-GVHD after
transplantation from MMRD or UD (BIII),
 Extensive c-GVHD when preceded by an a-
GVHD (AII).
Mold-active PAP is recommended.
 Posaconazole in GVHD (AI) (TDM advised for
oral solution)
 Voriconazole (BI) (TDM advised)
 Liposomal Amphotericin B (CIII)
 Caspofungin (CIII)
 Micafungin (CIII)
 Aerosolized amphotericin B plus ﬂuconazole
(CIII)
Standard risk All remaining patients not included in the high-
risk category (AI).
All remaining patients not included in the high-
risk category (BII).
Limited c-GVHD in patients who receive only a
nonsteroid immunosuppression and “de
novo” c-GVHD (BIII).
Candida active PAP is recommended.
Fluconazole (AI)
Voriconazole (BI)
Itraconazole(BI) Micafungin (BI)
Low risk No patient may be considered at low risk for IFD
during this phase.
No patient may be considered at low risk for IFD
during this phase.
Absence of any type of GVHD and no steroid
therapy (AII).
No PAP is recommended
PAP indicates primary antifungal prophylaxis; CB, cord blood; MMRD, mismatched related donor; UD, unrelated donor; a-GVHD, acute graft-versus-host disease; c-GVHD, chronic graft-versus-host disease; CMV, cytomeg-
alovirus; TDM, therapeutic drug monitoring; IFD, invasive fungal disease; PMN, polymorphonuclear neutrophil.
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replaced with a mold-active drug if high-risk condi-
tions for IFD occur. Itraconazole, micafungin, and vor-
iconazole proved to be as effective as ﬂuconazole in the
prophylaxis of Candida infections during the engraft-
ment phase in large controlled trials [43,55,56];
furthermore, micafungin is active on triazole-resistant
Candida strains and lacks clinically relevant drug-drug
interaction. Although these drugs may be considered
an alternative to PAP during the early phase after
transplantation in standard-risk patients, ﬂuconazole
should be preferred, considering the advantages in
cost (compared with micafungin and voriconazole)
and tolerability (compared with itraconazole and
voriconazole). In view of these considerations, the
EP agreed on a moderate recommendation for the
use of these drugs for the prevention of Candida in-
fections (BI).
2. A mold-active PAP should be used in high-risk patients
in any phase after transplantation. The evidence of ef-
ﬁcacy, different pharmacokinetic, drug-drug interac-
tion, and toxicity proﬁle of the various antifungal drugs
should be considered in the choice of PAP in each single
patient [52]. Posaconazole oral solution (600mg/day in
adults or 12 mg/kg/day in children) is the drug of
choice for patients with GVHD at high risk for IFD (AI).
This formulation of posaconazole has the potential
limitation of erratic absorption, especially in patients
with intestinal GVHD and/or diarrhea. Therefore, TDM
is recommended in such conditions. The upcoming
availability of posaconazole tablets with an improved
absorption and no need for TDM will probably extend
the use of this triazole in PAP [57]. In consideration of
the results of the above-mentioned controlled studies,
in which voriconazole showed some advantages
compared with ﬂuconazole and itraconazole, there is
moderate evidence for the use of voriconazole as PAP in
high-risk allo-HSCT recipients as an alternative to
posaconazole, particularly in the early phase after
transplantation (BI). Voriconazole may be preferred to
posaconazole in patients with impaired absorption (ie,
in patients with GVHD involving the gastrointestinal
tract), a condition potentially limiting the use of pos-
aconazole. It should be also considered that inter- and
intrapatient metabolic variability is a major concern in
voriconazole treatment and TDM is recommended,
especially in the pediatric population [58]. The few
retrospective experiences on the use of aerosolized
amphotericin B in association with ﬂuconazole, of
liposomal amphotericin B, and of the echinocandins
caspofungin and micafungin do not allow any recom-
mendation for the use of these drugs as PAP in high-
risk patients (CIII). Mold-active PAP should be
continued until discontinuation of steroid and any
other immunosuppressive therapy (BIII).
CONCLUSIONS
Most of trials of PAP in allo-HSCT have been performed in
populations with risk of developing IFD and results obtained
in these studies may be difﬁcult to apply in the different
types and phases of transplantation. As a consequence, most
clinical decisions continue to derive frompersonal experience
and subjective considerations [5,59,60]. The deﬁnition of the
level of risk for IFD associated with the various types and
phases of transplantation is the critical determinant of anyprevention strategy and represents theﬁrst step of a decision-
making PAP algorithm (Table 4). Considering the difﬁculty in
performing adequate interventional trials in subpopulations
of allo-HSCT patients, most of the information for planning
tailored prevention strategies in clinical practice must be
drawn from large epidemiological, possibly prospective
studies and the recent GITMO survey provides a useful esti-
mate of the current levels of infectious risk for IFDs in the
various transplantation subpopulations [2]. In the present
report, experts in the ﬁeld judged whether the body of evi-
dence from this GITMO study and recent literature was suf-
ﬁcient to provide information for the deﬁnition of new
recommendations for PAP in allo-HSCT recipients. The ques-
tions raisedbyand the conclusionsdrawn fromthis consensus
conference projectmay form the basis for improving efforts in
the prevention of IFDs in the allo-HSCT populations.
Current evidence from the literature is not able to give
comprehensive information on all clinical issues of the allo-
HSCT procedure; consequently, the present recommenda-
tions may be insufﬁcient to meet many clinical needs. A
continuous epidemiological update is needed to implement
the guidelines to be applied in the clinical practice.
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